Mosi Indications/Uses

MOSI is indicated for treatment of patients 1 year of age and older with bacterial conjunctivitis caused by susceptible strains of the following organisms: Gram-positive bacteria: Corynebacterium sp.,
Microbacterium sp.,
Micrococcus luteus [including erythromycin, gentamicin, tetracycline, and/or trimethoprim resistant strains],
Staphylococcus aureus [including methicillin, erythromycin, gentamicin, ofloxacin, tetracycline and/or trimethoprim resistant strains],
Staphlococcus epidermidis [including methicillin, erythromycin, gentamicin, ofloxacin, tetracycline and/or trimethoprim resistant strains],
Staphylococcus haemolyticus [including methicillin, erythromycin, gentamicin, ofloxacin, tetracycline and/or trimethoprim resistant strains],
Staphylococcus hominis [including methicillin, erythromycin, gentamicin, ofloxacin, tetracycline and/or trimethoprim resistant strains],
Staphylococcus warneri [including erythromycin resistant strains],
Streptococcus mitis [including penicillin, erythromycin, tetracycline and/or trimethoprim resistant strains],
Streptococcus pneumoniae [including penicillin, erythromycin, gentamicin, tetracycline and/or trimethoprim resistant strains],
Streptococcus viridans [including penicillin, erythromycin, tetracycline and/or trimethoprim resistant strains].
Gram-negative bacteria: Acinetobacter sp.,
Haemophilus "alconae" [including ampicillin resistant strains],
Haemophilus influenza [including ampicillin resistant strains],
Klebsiella pneumoniae,
Moraxella catarrhalis,
Pseudomonas aeruginosa.
Other microorganisms: Chlamydia trachomatis.
*Efficacy for this organism was studied in fewer than 10 infections.